The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.
 
Neil P. Shah
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; Pfizer; Plexxikon
 
Giuseppe Saglio
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
 
Andreas Hochhaus
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
 
Robyn Bilmes
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Li Li
Employment - Bristol-Myers Squibb; Novo Nordisk
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novo Nordisk
 
Jorge E. Cortes
Consulting or Advisory Role - Ambit BioSciences; Amphivena Therapeutics; ARIAD; Astellas Pharma; BiolineRx; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Teva (Inst)